{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:53Z","timestamp":1763018273389,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) are used widely for treating metastatic urothelial carcinoma (mUC). In practical settings, evidence is lacking on the efficacy of ICIs in some difficult-to-treat patients, such as those with end-stage renal disease (ESRD). Herein, we evaluate the safety and efficacy of ICIs for patients with mUC and ESRD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>For this retrospective study, patients with mUC who were given ICIs at Kaohsiung Chang Gang Memorial Hospital and Linkou Chang Gung Memorial Hospital between April 2016 and November 2019 were consecutively enrolled. All clinicopathologic data, treatment responses, and adverse events were recorded. The immune-related adverse events (AEs), objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared between ESRD and non-ESRD groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 129 patients with mUC were enrolled, with 11 patients categorized as the ESRD group. Among these patients with ESRD receiving ICIs, 7 of 11 (63.6%) had high-grade (grade \u22653) AEs, chiefly hematologic toxicity. Some rarely encountered AEs were noted, including toxic epidermal necrolysis, tuberculosis reactivation, ascites, and cytokine release syndrome. Patients in the ESRD group had numerically higher ORR (54.5% vs. 28.8%, p = 0.09), PFS (7.1 vs. 3.5 months, p = 0.42), and OS (not reached vs. 15.4 months) than the non-ESRD group. A multivariate Cox regression model demonstrated that leukocytosis (hazard ratio [HR]: 2.63; 95% confidence interval [CI]: 1.23\u20135.63; p = 0.01) and neutrophil-to-lymphocyte ratio (HR 2.91; 95% CI: 1.30\u20136.53; p = 0.01) were independent prognostic factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Administration of ICIs in patients with mUC and ESRD demonstrated a modest antitumor activity, and should be used with caution for increasing risk of hematologic toxicity.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2020.584834","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T06:35:05Z","timestamp":1606458905000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice"],"prefix":"10.3389","volume":"10","author":[{"given":"Ming-Chun","family":"Kuo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Jung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao-Lun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Jan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shau-Hsuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Che","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Tso","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsiung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Li","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2014","journal-title":"Int J Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study","volume":"17","author":"Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.6_suppl.286","article-title":"Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma [abstract]","volume":"35","author":"Powles","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/1756287218814100","article-title":"The continuing role of chemotherapy in the management of advanced urothelial cancer","volume":"10","author":"G\u00f3mez De Lia\u00f1o","year":"2018","journal-title":"Ther Adv Urol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11223","article-title":"Patients with urothelial carcinoma have poor renal outcome regardless of whether they receive nephrouretectomy","volume":"7","author":"Hung","year":"2016","journal-title":"Oncotarget"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2013.10.022","article-title":"Increased risk of urothelial cancer in young and middle aged patients with end-stage renal disease","volume":"114","author":"Wang","year":"2015","journal-title":"J Formos Med Assoc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0673-y","article-title":"Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review","volume":"37","author":"Cheun","year":"2019","journal-title":"Invest New Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2147\/CMAR.S73389","article-title":"Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease","volume":"7","author":"Cavalcante","year":"2015","journal-title":"Cancer Manage Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.06.009","article-title":"Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature","volume":"17","author":"Vitale","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy","volume":"16","author":"Postow","year":"2016","journal-title":"Am J Transplant"},{"key":"B17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.05.040","article-title":"Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis","volume":"70","author":"Carlo","year":"2016","journal-title":"Eur Urol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"bcr2016216426","DOI":"10.1136\/bcr-2016-216426","article-title":"Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis","volume":"2016","author":"Chang","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor Regression and Allograft Rejection after Administration of Anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.07.019","article-title":"Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature","volume":"48","author":"Jose","year":"2016","journal-title":"Transplant Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13420","article-title":"Successful treatment of metastatic clear cell carcinoma with nivolumab in a patient receiving dialysis treatment","volume":"24","author":"Tabei","year":"2017","journal-title":"Int J Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2017.06.007","article-title":"Donor-Derived Metastatic Melanoma and Checkpoint Inhibition","volume":"49","author":"Boyle","year":"2017","journal-title":"Transplant Proc"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e14553","article-title":"Anti-PD-1 therapy in patients with end-stage renal disease on dialysis: A single-center case series","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2018.03.005","article-title":"Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression","volume":"56","author":"Ishizuka","year":"2018","journal-title":"Respir Investig"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/1623957","article-title":"Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review","volume":"2018","author":"Ansari","year":"2018","journal-title":"Case Rep Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3452762","article-title":"Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis","volume":"2019","author":"Parisi","year":"2019","journal-title":"Case Rep Oncol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1159\/000504515","article-title":"Outcomes and Safety of Biweekly and Monthly Nivolumab in Patients with Metastatic Renal Cell Carcinoma and Dialysis: Three Case Reports and Literature Review","volume":"104","author":"Osm\u00e1n-Garc\u00eda","year":"2020","journal-title":"Urol Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.34067\/KID.0000422020","article-title":"Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature","volume":"1","author":"Hirsch","year":"2020","journal-title":"Kidney360"},{"key":"B32","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/j.ajkd.2020.02.451","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series","volume":"76","author":"Strohbehn","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"eaat2702","DOI":"10.1126\/scitranslmed.aat2702","article-title":"Tuberculosis following PD-1 blockade for cancer immunotherapy","volume":"11","author":"Barber","year":"2019","journal-title":"Sci Transl Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CJI.0000000000000236","article-title":"Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma","volume":"42","author":"Dimitriou","year":"2019","journal-title":"J Immunother"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000496933","article-title":"First Case of Cytokine Release Syndrome after Nivolumab for Gastric Cancer","volume":"12","author":"Oda","year":"2019","journal-title":"Case Rep Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e26642","DOI":"10.1002\/pbc.26642","article-title":"Severe cytokine release syndrome in a patient receiving PD-1-directed therapy","author":"Rotz","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.1182\/blood-2019-127586","article-title":"Cytokine Release Syndrome As a Rare Complication of Nivolumab: A Case Report","volume":"134","author":"Slota","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"58","author":"Centanni","year":"2019","journal-title":"Clin Pharmacokinet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.584834\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T06:35:07Z","timestamp":1606458907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2020.584834\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":40,"alternative-id":["10.3389\/fonc.2020.584834"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.584834","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"article-number":"584834"}}